BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Crown JP, Diéras V, Staroslawska E, Yardley DA, Bachelot T, Davidson N, Wildiers H, Fasching PA, Capitain O, Ramos M. Phase III trial of sunitinib in combination with capecitabine versus capecitabine monotherapy for the treatment of patients with pretreated metastatic breast cancer. J Clin Oncol. 2013;31:2870-2878. [PMID: 23857972 DOI: 10.1200/jco.2012.43.3391] [Cited by in Crossref: 101] [Cited by in F6Publishing: 45] [Article Influence: 12.6] [Reference Citation Analysis]
Number Citing Articles
1 Zhu A, Yuan P, Hu N, Li M, Wang W, Wang X, Yue J, Wang J, Luo Y, Ma F, Zhang P, Li Q, Xu B, Cao S, Lippi G, Naito Y, Osman MA, Marta GN, Franceschini G, Orlandi A. Phase II study of apatinib in combination with oral vinorelbine in heavily pretreated HER2-negative metastatic breast cancer and clinical implications of monitoring ctDNA. Cancer Biol Med 2021:j. [PMID: 34037346 DOI: 10.20892/j.issn.2095-3941.2020.0418] [Reference Citation Analysis]
2 Lacombe D, Burock S, Bogaerts J, Schoeffski P, Golfinopoulos V, Stupp R. The dream and reality of histology agnostic cancer clinical trials. Mol Oncol 2014;8:1057-63. [PMID: 25349876 DOI: 10.1016/j.molonc.2014.06.002] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
3 Liu B, Ding F, Liu Y, Xiong G, Lin T, He D, Zhang Y, Zhang D, Wei G. Incidence and risk of hypertension associated with vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: a comprehensive network meta-analysis of 72 randomized controlled trials involving 30013 patients. Oncotarget 2016;7:67661-73. [PMID: 27602778 DOI: 10.18632/oncotarget.11813] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 8.0] [Reference Citation Analysis]
4 Ghimirey N, Steele C, Czerniecki BJ, Koski GK, Showalter LE. Sunitinib Combined with Th1 Cytokines Potentiates Apoptosis in Human Breast Cancer Cells and Suppresses Tumor Growth in a Murine Model of HER-2pos Breast Cancer. Int J Breast Cancer 2021;2021:8818393. [PMID: 33936816 DOI: 10.1155/2021/8818393] [Reference Citation Analysis]
5 Lacombe D, Tejpar S, Salgado R, Cardoso F, Golfinopoulos V, Aust D, Folprecht G, Roth A, Stupp R. European perspective for effective cancer drug development. Nat Rev Clin Oncol 2014;11:492-8. [PMID: 24935010 DOI: 10.1038/nrclinonc.2014.98] [Cited by in Crossref: 35] [Cited by in F6Publishing: 25] [Article Influence: 5.0] [Reference Citation Analysis]
6 Zhang J, Zhang Y, Tang S, Jiang L, He Q, Hamblin LT, He J, Xu Z, Wu J, Chen Y, Liang H, Chen D, Huang Y, Wang X, Deng K, Jiang S, Zhou J, Xu J, Chen X, Liang W, He J. Systematic bias between blinded independent central review and local assessment: literature review and analyses of 76 phase III randomised controlled trials in 45 688 patients with advanced solid tumour. BMJ Open 2018;8:e017240. [PMID: 30206071 DOI: 10.1136/bmjopen-2017-017240] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
7 Arjaans M, Schröder CP, Oosting SF, Dafni U, Kleibeuker JE, de Vries EG. VEGF pathway targeting agents, vessel normalization and tumor drug uptake: from bench to bedside. Oncotarget 2016;7:21247-58. [PMID: 26789111 DOI: 10.18632/oncotarget.6918] [Cited by in Crossref: 67] [Cited by in F6Publishing: 62] [Article Influence: 22.3] [Reference Citation Analysis]
8 Xu L, Wu X, Hu C, Zhang Z, Zhang L, Liang S, Xu Y, Zhang F. A meta-analysis of combination therapy versus single-agent therapy in anthracycline- and taxane-pretreated metastatic breast cancer: results from nine randomized Phase III trials. Onco Targets Ther 2016;9:4061-74. [PMID: 27445497 DOI: 10.2147/OTT.S101423] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
9 Wragg JW, Heath VL, Bicknell R. Sunitinib Treatment Enhances Metastasis of Innately Drug-Resistant Breast Tumors. Cancer Res 2017;77:1008-20. [PMID: 28011623 DOI: 10.1158/0008-5472.CAN-16-1982] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 1.8] [Reference Citation Analysis]
10 Ferraz de Paiva RE, Vieira EG, Rodrigues da Silva D, Wegermann CA, Costa Ferreira AM. Anticancer Compounds Based on Isatin-Derivatives: Strategies to Ameliorate Selectivity and Efficiency. Front Mol Biosci 2020;7:627272. [PMID: 33614708 DOI: 10.3389/fmolb.2020.627272] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
11 El Sayed R, El Jamal L, El Iskandarani S, Kort J, Abdel Salam M, Assi H. Endocrine and Targeted Therapy for Hormone-Receptor-Positive, HER2-Negative Advanced Breast Cancer: Insights to Sequencing Treatment and Overcoming Resistance Based on Clinical Trials. Front Oncol 2019;9:510. [PMID: 31281796 DOI: 10.3389/fonc.2019.00510] [Cited by in Crossref: 21] [Cited by in F6Publishing: 14] [Article Influence: 10.5] [Reference Citation Analysis]
12 Zhang J, Zhang Y, Tang S, Liang H, Chen D, Jiang L, He Q, Huang Y, Wang X, Deng K, Jiang S, Zhou J, Xu J, Chen X, Liang W, He J. Evaluation bias in objective response rate and disease control rate between blinded independent central review and local assessment: a study-level pooled analysis of phase III randomized control trials in the past seven years. Ann Transl Med 2017;5:481. [PMID: 29299443 DOI: 10.21037/atm.2017.11.24] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
13 Hu N, Zhu A, Si Y, Yue J, Wang X, Wang J, Ma F, Xu B, Yuan P. A Phase II, Single-Arm Study of Apatinib and Oral Etoposide in Heavily Pre-Treated Metastatic Breast Cancer. Front Oncol 2020;10:565384. [PMID: 33659204 DOI: 10.3389/fonc.2020.565384] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Hulin JA, Gubareva EA, Jarzebska N, Rodionov RN, Mangoni AA, Tommasi S. Inhibition of Dimethylarginine Dimethylaminohydrolase (DDAH) Enzymes as an Emerging Therapeutic Strategy to Target Angiogenesis and Vasculogenic Mimicry in Cancer. Front Oncol 2019;9:1455. [PMID: 31993367 DOI: 10.3389/fonc.2019.01455] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 7.0] [Reference Citation Analysis]
15 Levin MK, Wang K, Yelensky R, Cao Y, Ramos C, Hoke N, Pippen J Jr, Blum JL, Brooks B, Palmer G, Palma N, Balasubramanian S, Ross JS, O'Shaughnessy J. Genomic alterations in DNA repair and chromatin remodeling genes in estrogen receptor-positive metastatic breast cancer patients with exceptional responses to capecitabine. Cancer Med 2015;4:1289-93. [PMID: 25871911 DOI: 10.1002/cam4.464] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
16 Andreopoulou E, Schweber SJ, Sparano JA, McDaid HM. Therapies for triple negative breast cancer. Expert Opin Pharmacother 2015;16:983-98. [PMID: 25881743 DOI: 10.1517/14656566.2015.1032246] [Cited by in Crossref: 53] [Cited by in F6Publishing: 49] [Article Influence: 8.8] [Reference Citation Analysis]
17 Marmé F, Schneeweiss A. Targeted Therapies in Triple-Negative Breast Cancer. Breast Care (Basel) 2015;10:159-66. [PMID: 26557820 DOI: 10.1159/000433622] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 5.7] [Reference Citation Analysis]
18 Dong M, Wang R, Sun P, Zhang D, Zhang Z, Zhang J, Tse G, Zhong L. Clinical significance of hypertension in patients with different types of cancer treated with antiangiogenic drugs. Oncol Lett 2021;21:315. [PMID: 33692847 DOI: 10.3892/ol.2021.12576] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 Reguera-Nuñez E, Xu P, Chow A, Man S, Hilberg F, Kerbel RS. Therapeutic impact of Nintedanib with paclitaxel and/or a PD-L1 antibody in preclinical models of orthotopic primary or metastatic triple negative breast cancer. J Exp Clin Cancer Res 2019;38:16. [PMID: 30635009 DOI: 10.1186/s13046-018-0999-5] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 7.0] [Reference Citation Analysis]
20 Galanis A, Levis M. Inhibition of c-Kit by tyrosine kinase inhibitors. Haematologica 2015;100:e77-9. [PMID: 25425690 DOI: 10.3324/haematol.2014.117028] [Cited by in Crossref: 61] [Cited by in F6Publishing: 51] [Article Influence: 8.7] [Reference Citation Analysis]
21 Bachelot T, Garcia-Saenz JA, Verma S, Gutierrez M, Pivot X, Kozloff MF, Prady C, Huang X, Khosravan R, Wang Z, Cesari R, Tassell V, Kern KA, Blay JY, Lluch A. Sunitinib in combination with trastuzumab for the treatment of advanced breast cancer: activity and safety results from a phase II study. BMC Cancer 2014;14:166. [PMID: 24606768 DOI: 10.1186/1471-2407-14-166] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
22 Bridgeman VL, Vermeulen PB, Foo S, Bilecz A, Daley F, Kostaras E, Nathan MR, Wan E, Frentzas S, Schweiger T, Hegedus B, Hoetzenecker K, Renyi-Vamos F, Kuczynski EA, Vasudev NS, Larkin J, Gore M, Dvorak HF, Paku S, Kerbel RS, Dome B, Reynolds AR. Vessel co-option is common in human lung metastases and mediates resistance to anti-angiogenic therapy in preclinical lung metastasis models. J Pathol 2017;241:362-74. [PMID: 27859259 DOI: 10.1002/path.4845] [Cited by in Crossref: 94] [Cited by in F6Publishing: 85] [Article Influence: 18.8] [Reference Citation Analysis]
23 Li Q, Kan X, Yin J, Sun L, Wang Y, Li Y, Yang Q, Xiao H, Chen Y, Weng X, Cai W, Zhu X. Chamaejasmine B Induces the Anergy of Vascular Endothelial Cells to VEGFA Pro-angiogenic Signal by Autophagic Regulation of VEGFR2 in Breast Cancer. Front Pharmacol 2017;8:963. [PMID: 29403376 DOI: 10.3389/fphar.2017.00963] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
24 Sridharan V, Thomas CJ, Cao M, Melnyk SB, Pavliv O, Joseph J, Singh SP, Sharma S, Moros EG, Boerma M. Effects of local irradiation combined with sunitinib on early remodeling, mitochondria, and oxidative stress in the rat heart. Radiother Oncol 2016;119:259-64. [PMID: 27072940 DOI: 10.1016/j.radonc.2016.03.027] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
25 Lehmann BD, Pietenpol JA. Identification and use of biomarkers in treatment strategies for triple-negative breast cancer subtypes. J Pathol. 2014;232:142-150. [PMID: 24114677 DOI: 10.1002/path.4280] [Cited by in Crossref: 227] [Cited by in F6Publishing: 212] [Article Influence: 32.4] [Reference Citation Analysis]
26 Han L, Korangath P, Nguyen NK, Diehl A, Cho S, Teo WW, Cope L, Gessler M, Romer L, Sukumar S. HEYL Regulates Neoangiogenesis Through Overexpression in Both Breast Tumor Epithelium and Endothelium. Front Oncol 2020;10:581459. [PMID: 33520697 DOI: 10.3389/fonc.2020.581459] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
27 Reinwald M, Boch T, Hofmann WK, Buchheidt D. Risk of Infectious Complications in Hemato-Oncological Patients Treated with Kinase Inhibitors. Biomark Insights 2015;10:55-68. [PMID: 27127405 DOI: 10.4137/BMI.S22430] [Cited by in Crossref: 8] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
28 Scarpelli M, Rampurwala M, Eickhoff J, Carmichael L, Heideman J, Binger K, Kolesar J, Perlman S, Harrow K, Dukart G, Liang C, Jeraj R, Liu G, Bruce JY. Pharmacodynamic study using FLT PET/CT in advanced solid malignancies treated with a sequential combination of X-82 and docetaxel. Cancer Chemother Pharmacol 2018;82:211-9. [PMID: 29802443 DOI: 10.1007/s00280-018-3599-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
29 Kuczynski EA, Reynolds AR. Vessel co-option and resistance to anti-angiogenic therapy. Angiogenesis 2020;23:55-74. [PMID: 31865479 DOI: 10.1007/s10456-019-09698-6] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 7.5] [Reference Citation Analysis]
30 Argyros O, Karampelas T, Varela A, Asvos X, Papakyriakou A, Agalou A, Beis D, Davos CH, Fokas D, Tamvakopoulos C. Targeting of the breast cancer microenvironment with a potent and linkable oxindole based antiangiogenic small molecule. Oncotarget 2017;8:37250-62. [PMID: 28422745 DOI: 10.18632/oncotarget.16763] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
31 Ribatti D, Nico B, Ruggieri S, Tamma R, Simone G, Mangia A. Angiogenesis and Antiangiogenesis in Triple-Negative Breast cancer. Transl Oncol 2016;9:453-7. [PMID: 27751350 DOI: 10.1016/j.tranon.2016.07.002] [Cited by in Crossref: 59] [Cited by in F6Publishing: 56] [Article Influence: 11.8] [Reference Citation Analysis]
32 Varinska L, Gal P, Mojzisova G, Mirossay L, Mojzis J. Soy and breast cancer: focus on angiogenesis. Int J Mol Sci 2015;16:11728-49. [PMID: 26006245 DOI: 10.3390/ijms160511728] [Cited by in Crossref: 78] [Cited by in F6Publishing: 57] [Article Influence: 13.0] [Reference Citation Analysis]
33 Paez-Ribes M, Man S, Xu P, Kerbel RS. Development of Patient Derived Xenograft Models of Overt Spontaneous Breast Cancer Metastasis: A Cautionary Note. PLoS One 2016;11:e0158034. [PMID: 27355476 DOI: 10.1371/journal.pone.0158034] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 3.4] [Reference Citation Analysis]
34 Peng D, Tanikawa T, Li W, Zhao L, Vatan L, Szeliga W, Wan S, Wei S, Wang Y, Liu Y, Staroslawska E, Szubstarski F, Rolinski J, Grywalska E, Stanisławek A, Polkowski W, Kurylcio A, Kleer C, Chang AE, Wicha M, Sabel M, Zou W, Kryczek I. Myeloid-Derived Suppressor Cells Endow Stem-like Qualities to Breast Cancer Cells through IL6/STAT3 and NO/NOTCH Cross-talk Signaling. Cancer Res 2016;76:3156-65. [PMID: 27197152 DOI: 10.1158/0008-5472.CAN-15-2528] [Cited by in Crossref: 123] [Cited by in F6Publishing: 81] [Article Influence: 24.6] [Reference Citation Analysis]
35 Vasudev NS, Reynolds AR. Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions. Angiogenesis. 2014;17:471-94. [PMID: 24482243 DOI: 10.1007/s10456-014-9420-y] [Cited by in Crossref: 415] [Cited by in F6Publishing: 351] [Article Influence: 59.3] [Reference Citation Analysis]
36 Nishijima TF, Suzuki M, Muss HB. A comparison of toxicity profiles between the lower and standard dose capecitabine in breast cancer: a systematic review and meta-analysis. Breast Cancer Res Treat 2016;156:227-36. [PMID: 26988358 DOI: 10.1007/s10549-016-3756-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
37 Shao F, Sun H, Deng CX. Potential therapeutic targets of triple-negative breast cancer based on its intrinsic subtype. Oncotarget. 2017;8:73329-73344. [PMID: 29069872 DOI: 10.18632/oncotarget.20274] [Cited by in Crossref: 37] [Cited by in F6Publishing: 37] [Article Influence: 9.3] [Reference Citation Analysis]
38 Beltrán Hernández I, Kromhout JZ, Teske E, Hennink WE, van Nimwegen SA, Oliveira S. Molecular targets for anticancer therapies in companion animals and humans: what can we learn from each other? Theranostics 2021;11:3882-97. [PMID: 33664868 DOI: 10.7150/thno.55760] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
39 Ghatalia P, Je Y, Kaymakcalan MD, Sonpavde G, Choueiri TK. QTc interval prolongation with vascular endothelial growth factor receptor tyrosine kinase inhibitors. Br J Cancer 2015;112:296-305. [PMID: 25349964 DOI: 10.1038/bjc.2014.564] [Cited by in Crossref: 79] [Cited by in F6Publishing: 57] [Article Influence: 11.3] [Reference Citation Analysis]
40 Yadav BS, Sharma SC, Chanana P, Jhamb S. Systemic treatment strategies for triple-negative breast cancer. World J Clin Oncol 2014;5:125-33. [PMID: 24829859 DOI: 10.5306/wjco.v5.i2.125] [Cited by in CrossRef: 72] [Cited by in F6Publishing: 65] [Article Influence: 10.3] [Reference Citation Analysis]
41 Stalker L, Pemberton J, Moorehead RA. Inhibition of proliferation and migration of luminal and claudin-low breast cancer cells by PDGFR inhibitors. Cancer Cell Int 2014;14:89. [PMID: 25253994 DOI: 10.1186/s12935-014-0089-5] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.9] [Reference Citation Analysis]
42 Wang Z, Wang M, Yang F, Nie W, Chen F, Xu J, Guan X. Multitargeted antiangiogenic tyrosine kinase inhibitors combined to chemotherapy in metastatic breast cancer: a systematic review and meta-analysis. Eur J Clin Pharmacol 2014;70:531-8. [PMID: 24562632 DOI: 10.1007/s00228-014-1654-5] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
43 Krchniakova M, Skoda J, Neradil J, Chlapek P, Veselska R. Repurposing Tyrosine Kinase Inhibitors to Overcome Multidrug Resistance in Cancer: A Focus on Transporters and Lysosomal Sequestration. Int J Mol Sci 2020;21:E3157. [PMID: 32365759 DOI: 10.3390/ijms21093157] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
44 Madu CO, Wang S, Madu CO, Lu Y. Angiogenesis in Breast Cancer Progression, Diagnosis, and Treatment. J Cancer 2020;11:4474-94. [PMID: 32489466 DOI: 10.7150/jca.44313] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 18.0] [Reference Citation Analysis]
45 Wang D, Xiao F, Feng Z, Li M, Kong L, Huang L, Wei Y, Li H, Liu F, Zhang H, Zhang W. Sunitinib facilitates metastatic breast cancer spreading by inducing endothelial cell senescence. Breast Cancer Res 2020;22:103. [PMID: 32993785 DOI: 10.1186/s13058-020-01346-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]